Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
0.18
-0.00 (-1.82%)
Market open: Aug 12, 2026, 1:38 PM EDT
0.18
-0.00 (-0.17%)
Previous after-hours: Aug 11, 2026, 7:58 PM EDT
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-07-27 | 8-K | goss-20260723.htm |
| 2026-07-15 | 8-K | goss-20260714.htm |
| 2026-07-01 | 8-K | goss-20260701.htm |
| 2026-06-17 | 8-K | goss-20260617.htm |
| 2026-06-09 | DEF 14A | goss-20260609.htm |
| 2026-06-05 | 8-K | goss-20260604.htm |
| 2026-06-02 | 8-K | goss-20260602.htm |
| 2026-05-18 | PRE 14A | goss-20260518.htm |
| 2026-05-18 | DEFA14A | a20260518-gossxdefa14a.htm |
| 2026-05-18 | 8-K | goss-20260518.htm |